Thomas C Mccarty

US Patent:

20190184000, Jun 20, 2019

Filed:

Dec 12, 2016

Appl. No.:

16/061316

Inventors:

- Bethesda MD, US
Thomas Charles McCarty - Bethesda MD, US

International Classification:

A61K 39/12
C12N 7/00

Abstract:

Reported herein are novel recombinant respiratory syncytial viruses (RSV) having an attenuated phenotype in which the native positions of the NS1 and/or NS2 genes in the RSV genome are shifted to a higher position, that is at positions that are more distal to the promoter. The changes in the gene positions may be present in combination with mutations at other loci to achieve desired levels of attenuation and immunogenicity. The recombinant RSV strains described here are suitable for use as live-attenuated RSV vaccines. Also provided are polynucleotide sequences capable of encoding the described viruses, as well as methods for producing and using the viruses.